Infinity Pharmaceuticals (NASDAQ:INFI) Will Have To Spend Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenue, if you held shares since 2005, you’d have done very well indeed. Having said that, unprofitable companies are risky because they could potentially burn through all their cash and become distressed.
So should Infinity Pharmaceuticals (NASDAQ:INFI) shareholders be worried about its cash burn? For …
